Director, Division of Hematology Marjory J. Johnson Chair of Hematology Translational Research, Division of Hematology Co-Executive Director, Cancer and Blood Diseases Institute Associate Director
Pediatric Hematology & Oncology
Dr. Russell Ware, MD
|
|
Give Review
Russell Ware is an expert in the field of Pediatric Hematology & Oncology. He went to medical school at Duke University School of Medicine. Duke University School of Medicine is a top medical college. Duke University School of Medicine has a rank of 8 in research and a 29 in primary care Russell Ware is a published doctor and has 90 publications published. The lastest was: 'Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing...'
Publications
- Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing...
- Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
- Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
- Characteristics of a rapid, point-of-care lateral flow immunoassay for the diagnosis of sickle cell disease.
- Hydroxyurea therapy for sickle cell Anemia.
- Evidence gaps in the management of sickle cell disease: A summary of needed research.
- Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload.
- From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell Anemia.
- Predictors of splenic function preservation in children with sickle cell Anemia treated with hydroxyurea.
- Shared decision making for hydroxyurea treatment initiation in children with sickle cell Anemia.
- Immunologic Effects of Hydroxyurea in Sickle Cell Anemia.
- Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell Anemia: results from the SWiTCH trial.
- Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
- Pain and other non-neurological adverse events in children with sickle cell Anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions ...
- A prospective newborn screening and treatment program for sickle cell Anemia in luanda, angola.
- RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia.
- Current Management of Sickle Cell Anemia.
- Hydroxycarbamide: Clinical aspects.
- Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell Anemia.
- Genetic mapping and exome sequencing identify two mutations associated with stroke protection in pediatric patients with sickle cell Anemia.
- Long Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Ce...
- The clinical and laboratory spectrum of Hb C [?6(A3)Glu?Lys, GAG>AAG] disease.
- 50 years ago in the journal of pediatrics vitamin a deficiency in african children in northern rhodesia.
- In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology.
- Hydroxyurea therapy of a murine model of sickle cell Anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.
- A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression.
- Epigenetic and molecular profiles of erythroid cells following hydroxyurea treatment in Sickle Cell Anemia.
- Hemodynamic responses to visual stimulation in children with sickle cell Anemia.
- Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell Anemia.
- Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell Anemia, stroke, and iron ov...
- Thrombopoiesis: new ITP paradigm?
- A pilot study of subcutaneous decitabine in β-Thalassemia intermedia.
- Glomerular hyperfiltration and albuminuria in children with sickle cell Anemia.
- IgA-mediated autoimmune hemolytic Anemia in an infant.
- Hydroxyurea for sickle cell Anemia: what have we learned and what questions still remain?
- Genetic predictors for stroke in children with sickle cell Anemia.
- Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell Anemia and iron overload.
- Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
- Partial splenectomy for hereditary spherocytosis: a multi-institutional review.
- The diagnostic dilemma of congenital unstable hemoglobinopathies.
- Ventricular diastolic dysfunction in sickle cell Anemia is common but not associated with myocardial iron deposition.
- Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
- How I use hydroxyurea to treat young patients with sickle cell Anemia.
- The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
- Hydroxyurea for children with sickle cell disease.
- Preface. Developments in pediatric oncology and hematology.
- Brown recluse spider (Loxosceles reclusa) envenomation leading to acute hemolytic Anemia in six adolescents.
- Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: Report of two patients.
- Simultaneous acute splenic sequestration and transient aplastic crisis in children with sickle cell disease.
- Microarray analysis of liver gene expression in iron overloaded patients with sickle cell Anemia and beta-thalassemia.
- R2* magnetic resonance imaging of the liver in patients with iron overload.
- A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell Anemia.
- Advances in the use of hydroxyurea.
- Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell Anemia.
- A novel G6PD mutation leading to chronic hemolytic Anemia.
- UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell Anemia.
- Pediatric hematology and pediatric oncology.
- Partial splenectomy for children with congenital hemolytic Anemia and massive splenomegaly.
- Beta-Thalassemia intermedia due to compound heterozygosity for two beta-globin gene promoter mutations, including a novel TATA box deletion.
- Preservation of spleen and brain function in children with sickle cell Anemia treated with hydroxyurea.
- Defective binding of factor XI-N248 to activated human platelets.
- Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell Anemia.
- Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease.
- Pelger-Huët anomaly in a child with 1q42.3-44 deletion.
- Hemoglobinopathies mimicking Hb S/beta-Thalassemia: Hb S/S with alpha-Thalassemia and Hb S/Volga.
- Enalapril and hydroxyurea therapy for children with sickle nephropathy.
- Long-term hydroxyurea therapy for infants with sickle cell Anemia: the HUSOFT extension study.
- Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
- Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell Anemia using hydroxyurea and phlebotomy.
- Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.
- Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
- Chemical and functional analysis of hydroxyurea oral solutions.
- Acute parvovirus B19 infection mimicking congenital dyserythropoietic Anemia.
- Malignancy in patients with sickle cell disease.
- Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease.
- Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
- Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency.
- Subclinical parvovirus B19 infection in children with sickle cell Anemia.
- UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell Anemia.
- Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria.
- Clinical and hematologic benefits of partial splenectomy for congenital hemolytic Anemias in children.
- Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel...
- The hematopoietic defect in PNH is not due to defective stroma, but is due to defective progenitor cells.
- Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly).
- Interpretation of fetal hemoglobin only on newborn screening for hemoglobinopathy.
- Neurocognitive development of young children with sickle cell disease through three years of age.
- Effect of hydroxyurea on growth in children with sickle cell Anemia: results of the HUG-KIDS Study.
- Predictors of fetal hemoglobin response in children with sickle cell Anemia receiving hydroxyurea therapy.
- Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell Anemia.
Schools
Duke University
Baylor College Of Med
Conditions Treated
- Anemia
- Thalassemia
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
Duke University Hospital -
Baylor College of Medicine -
Duke University School of Medicine
Hospital
-
Cincinnati Children's Hospital Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Lionel M. Chow, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Denise M. Adams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin Mizukawa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah E. Fitzgerald, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beatrice C. Lampkin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajaram Nagarajan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kasiani Myers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Theodosia A. Kalfa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aharon Gefen, MD |
|
|
Dr. Ralph Salloum, MD
This Doctor is OpenDoctor Recommended.
|